Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ELVN
- Price
- 21.30
- Stock movement up
- +0.18 (0.92%)
- Company name
- Enliven Therapeutics Inc.
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.18B
- Ent value
- 1.09B
- Price/Sales
- 2670.98
- Price/Book
- 4.08
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 10.90%
- 1 year return
- -15.68%
- 3 year return
- 1.96%
- 5 year return
- -43.00%
- 10 year return
- -
Last updated: 2025-09-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ELVN does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 2670.98 |
| Price to Book | 4.08 |
| EV to Sales | 2481.00 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 59.24M |
| EPS (TTM) | -1.77 |
| FCF per share (TTM) | -2.41 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 440.00K |
| Gross profit (TTM) | 205.00K |
| Operating income (TTM) | -100.39M |
| Net income (TTM) | -85.21M |
| EPS (TTM) | -1.77 |
| EPS (1y forward) | -1.64 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 46.59% |
| Operating margin (TTM) | -22815.23% |
| Profit margin (TTM) | -19366.82% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 100.62M |
| Net receivables | 0.00 |
| Total current assets | 297.00M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 1.54M |
| Total assets | 305.43M |
| Accounts payable | 1.02M |
| Short/Current long term debt | 85.00K |
| Total current liabilities | 17.03M |
| Total liabilities | 17.03M |
| Shareholder's equity | 288.40M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -116.46M |
| Capital expenditures (TTM) | 58.00K |
| Free cash flow (TTM) | -116.52M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -29.55% |
| Return on Assets | -27.90% |
| Return on Invested Capital | -29.54% |
| Cash Return on Invested Capital | -40.39% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 19.66 |
| Daily high | 20.27 |
| Daily low | 19.30 |
| Daily Volume | 809K |
| All-time high | 877.92 |
| 1y analyst estimate | 41.25 |
| Beta | 1.03 |
| EPS (TTM) | -1.77 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 6 Nov 2025 |
Downside potential
Loading...
Downside potential data
| ELVN | S&P500 | |
| Current price drop from All-time high | -97.74% | -1.46% |
| Highest price drop | -98.85% | -56.47% |
| Date of highest drop | 12 Dec 2023 | 9 Mar 2009 |
| Avg drop from high | -86.77% | -10.99% |
| Avg time to new high | 68 days | 12 days |
| Max time to new high | 1306 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
1.18B
Marketcap category
Small-cap
Description
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a CNS penetrant and irreversible HER2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 driven cancers and solid tumors. The company is headquartered in Boulder, Colorado.
Employees
63
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page